Role of plasminogen activator inhibitor-1 in glucocorticoid-induced diabetes and osteopenia in mice

Diabetes

Volumn 64, Issue 6, 2015, Pages 2194-2206

  Tamura, Yukinori ^a   Kawao, Naoyuki ^a   Yano, Masato ^a   Okada, Kiyotaka ^a   Okumoto, Katsumi ^a   Chiba, Yasutaka ^b   Matsuo, Osamu ^a   Kaji, Hiroshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINDAI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN PHOSPHORYLATION; WHITE ADIPOSE TISSUE; 3T3 CELL LINE; ANIMAL; BLEEDING DISORDER; CELL LINE; CHEMICALLY INDUCED; DEFICIENCY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HEPG2 CELL LINE; HUMAN; KNOCKOUT MOUSE; METABOLIC BONE DISEASE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

3T3-L1 CELLS; ANIMALS; BONE DISEASES, METABOLIC; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; FEMALE; GLUCOCORTICOIDS; HEMORRHAGIC DISORDERS; HEP G2 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; PLASMINOGEN ACTIVATOR INHIBITOR 1; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84981516062     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1192     Document Type: Article

References (50)

1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005;353:1711-1723.
2. Strehl C, Buttgereit F. Optimized glucocorticoid therapy: Teaching old drugs new tricks. Mol Cell Endocrinol 2013;380:32-40.
3. van Raalte DH, Ouwens DM, Diamant M. Novel insights into glucocorticoidmediated diabetogenic effects: Towards expansion of therapeutic options? Eur J Clin Invest 2009;39:81-93.
4. Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects and systemic implications. Trends Endocrinol Metab 2014;25:197-211.
5. Kuo T, Harris CA, Wang JC. Metabolic functions of glucocorticoid receptor in skeletal muscle. Mol Cell Endocrinol 2013;380:79-88.
6. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroidinduced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-720.
7. Yuen KC, Chong LE, Riddle MC. Influence of glucocorticoids and growth hormone on insulin sensitivity in humans. Diabet Med 2013;30:651-663.
8. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011;365:62-70.
9. Moutsatsou P, Kassi E, Papavassiliou AG. Glucocorticoid receptor signaling in bone cells. Trends Mol Med 2012;18:348-359.
10. Hasselgren PO, Alamdari N, Aversa Z, Gonnella P, Smith IJ, Tizio S. Corticosteroids and muscle wasting: Role of transcription factors, nuclear cofactors, and hyperacetylation. Curr Opin Clin Nutr Metab Care 2010;13:423-428.
11. Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm Res 2009;72(Suppl. 1):36-41.
12. Conde J, Scotece M, Gómez R, et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011;37:413-420.
13. Mathieu P, Lemieux I, Després JP. Obesity, inflammation, and cardiovascular risk. Clin Pharmacol Ther 2010;87:407-416.
14. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor- Type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004;91:861-872.
15. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53: 336-346.
16. Tamura Y, Kawao N, Okada K, et al. Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice. Diabetes 2013;62: 3170-3179.
17. Naderi J, Bernreuther C, Grabinski N, et al. Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis. Am J Pathol 2009;175:763-771.
18. Koh TJ, Bryer SC, Pucci AM, Sisson TH. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 2005;289:C217-C223.
19. Krause MP, Moradi J, Nissar AA, Riddell MC, Hawke TJ. Inhibition of plasminogen activator inhibitor-1 restores skeletal muscle regeneration in untreated type 1 diabetic mice. Diabetes 2011;60:1964-1972.
20. Erem C, Nuhoglu I, Yilmaz M, et al. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin- Activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009;32:169-174.
21. Darmon P, Dadoun F, Boullu-Ciocca S, Grino M, Alessi MC, Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Physiol Endocrinol Metab 2006;291:E995-E1002.
22. Carmeliet P, Moons L, Lijnen R, et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice. Circulation 1997;96:3180-3191.
23. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest 2012;122:4172-4189.
24. Herrmann M, Henneicke H, Street J, et al. The challenge of continuous exogenous glucocorticoid administration in mice. Steroids 2009;74:245-249.
25. Tamura Y, Kawao N, Yano M, Okada K, Matsuo O, Kaji H. Plasminogen activator inhibitor-1 deficiency ameliorates insulin resistance and hyperlipidemia but not bone loss in obese female mice. Endocrinology 2014;155:1708-1717.
26. Tamura Y, Sugimoto M, Murayama T, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008;28:2195-2201.
27. Kawao N, Tamura Y, Okumoto K, et al. Plasminogen plays a crucial role in bone repair. J Bone Miner Res 2013;28:1561-1574.
28. Miki H, Yamauchi T, Suzuki R, et al. Essential role of insulin receptor substrate 1 (IRS-1) and IRS-2 in adipocyte differentiation. Mol Cell Biol 2001;21: 2521-2532.
29. Tanaka K, Matsumoto E, Higashimaki Y, et al. Role of osteoglycin in the linkage between muscle and bone. J Biol Chem 2012;287:11616-11628.
30. Pan Y, Shu JL, Gu HF, et al. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol 2013;367:116-123.
31. Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol 2000;20:1150-1154.
32. Miao H, Zhang Y, Lu Z, Liu Q, Gan L. FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes. Inflamm Res 2012;61:349-358.
33. Zhang ZF, Li Q, Liang J, et al. Epigallocatechin-3-O-gallate (EGCG) protects the insulin sensitivity in rat L6 muscle cells exposed to dexamethasone condition. Phytomedicine 2010;17:14-18.
34. Seki T, Miyasu T, Noguchi T, et al. Reciprocal regulation of tissue- Type and urokinase- Type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes. J Cell Physiol 2001;189:72-78.
35. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-791.
36. López-Alemany R, Redondo JM, Nagamine Y, Muñoz-Cánoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003;270:814-821.
37. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-469.
38. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild- Type mice. Proc Natl Acad Sci U S A 2008;105:5266-5270.
39. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592-5599.
40. Dovio A, Perazzolo L, Osella G, et al. Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short- Term glucocorticoid therapy in young patients with multiple sclerosis. J Clin Endocrinol Metab 2004;89:4923-4928.
41. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids and the osteoclast. Ann N Y Acad Sci 2007;1116:335-339.
42. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006;116:2152-2160.
43. Kaji H. Interaction between muscle and bone. J Bone Metab 2014;21:29-40.
44. Kaji H. Linkage between muscle and bone: common catabolic signals resulting in osteoporosis and sarcopenia. Curr Opin Clin Nutr Metab Care 2013;16:272-277.
45. Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
46. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost 2008;100:992-1006.
47. Konkle BA, Schuster SJ, Kelly MD, et al. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992;79:2636-2642.
48. Oishi K, Ohkura N, Matsuda J, Ishida N. Food deprivation induces adipose plasminogen activator inhibitor-1 (PAI-1) expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice. Thromb Haemost 2007;98:864-870.
49. Siegel C, Turtzo C, McCullough LD. Sex differences in cerebral ischemia: possible molecular mechanisms. J Neurosci Res 2010;88:2765-2774.
50. Karasik D, Ferrari SL. Contribution of gender-specific genetic factors to osteoporosis risk. Ann Hum Genet 2008;72:696-714.